Lung cancer combo trial halted early: what happened?

NCT ID NCT06267001

Terminated Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 39 times

Summary

This study tested whether adding tiragolumab to atezolizumab could help prevent lung cancer from returning after surgery and chemotherapy. It included 56 adults with a specific type of lung cancer (PD-L1 positive, stages IIB to IIIB). The trial was terminated early, so results are limited. The main goal was to check safety and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Asan Medical Center

Seoul, 05505, South Korea
Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji

Bakirkoy / Istanbul, 34147, Turkey (Türkiye)
Centro Oncologico Korben

Ciudad Autonoma Buenos Aires, C1426AGE, Argentina
Changzhou First People's Hospital

Changzhou, 213003, China
Crio - Centro Regional Integrado de Oncologia

Fortaleza, Ceará, 60336-232, Brazil
E-DA Hospital

Kaohsiung City, 824, Taiwan
Hiroshima University Hospital

Hiroshima, 734-8551, Japan
Hospital Nossa Senhora da Conceicao

Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
Hospital de Cancer de Barretos

Barretos, São Paulo, 14784-400, Brazil
Hospital de Clínicas de Passo Fundo

Passo Fundo, Rio Grande do Sul, 99010-260, Brazil
Instytut Gruzlicy I Chorob Pluc

Warsaw, 01-138, Poland
Kindai University Hospital

Osaka, 589-8511, Japan
Korea University Guro Hospital

Seoul, 08308, South Korea
Kyungpook National University Chilgok Hospital

Daegu, 41404, South Korea
Liaoning Provincial Cancer Hospital

Shengyang, 110042, China
Monash Health

Clayton, Victoria, 3168, Australia
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

Nanjing, 210008, China
National Taiwan University Cancer Center

Zhongzheng Dist., 106, Taiwan
Ningbo No.2 Hospital

Ningbo, DUMMY_VALUE, China
Nucleo de Oncologia da Bahia - NOB

Salvador, Bahia, Estado de Bahia, 40170-380, Brazil
Ospedale P. Pederzoli Casa di cura Privata

Peschiera Del Garda (VR), Veneto, 37019, Italy
Pusan National University Hospital

Busan, 602-739, South Korea
Pusan National University Yangsan Hospital

Gyeongsangnam-do, 50612, South Korea
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Bundang Hospital

Seongnam-si, 463-707, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea
Shandong Cancer Hospital

Jinan, 250117, China
St. Vincent's Hospital

Gyeonggi-do, 16247, South Korea
Sunshine Coast University Hospital

Birtinya, Queensland, 4575, Australia
Taichung Veterans General Hospital

Taichung, 407, Taiwan
The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, 510080, China
Tianjin Cancer Hospital

Tianjin, 300060, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, 430030, China
Vajira Hospital

Bangkok, 10300, Thailand
Yunnan Cancer Hospital

Kunming, 650118, China
Zhejiang Cancer Hospital

Zhejiang, 310022, China

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC) NON-SMALL CELL LUNG CANCER (NSCLC)